Antithrombotic medications and the etiology of intracerebral hemorrhage: MUCH-Italy. by Pezzini, A et al.
DOI 10.1212/WNL.0000000000000108
2014;82;529-535 Published Online before print January 15, 2014Neurology 
Alessandro Pezzini, Mario Grassi, Maurizio Paciaroni, et al. 
hemorrhage: MUCH-Italy
Antithrombotic medications and the etiology of intracerebral
This information is current as of January 15, 2014
 http://www.neurology.org/content/82/6/529.full.html
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
since 1951, it is now a weekly with 48 issues per year. Copyright © 2014 American Academy of 
® is the official journal of the American Academy of Neurology. Published continuouslyNeurology 
Alessandro Pezzini, MD
Mario Grassi, PhD
Maurizio Paciaroni, MD
Andrea Zini, MD
Giorgio Silvestrelli, MD,
PhD
Elisabetta Del Zotto,
MD, PhD
Valeria Caso, MD, PhD
Maria Luisa Dell’Acqua,
MD
Alessia Giossi, MD
Irene Volonghi, MD
Anna Maria Simone, MD
Alessia Lanari, MD, PhD
Paolo Costa, MD
Loris Poli, MD
Andrea Morotti, MD
Valeria De Giuli, MD
Daniele Pepe, PhD
Massimo Gamba, MD
Alfonso Ciccone, MD
Marco Ritelli, PhD
Marina Colombi, PhD
Giancarlo Agnelli, MD,
PhD
Alessandro Padovani,
MD, PhD
On behalf of the
Multicenter Study on
Cerebral Hemorrhage
in Italy (MUCH-Italy)
Investigators
Correspondence to
Dr. Pezzini:
ale_pezzini@hotmail.com or
alessandro.pezzini@med.unibs.it
Supplemental data at
www.neurology.org
Antithrombotic medications and the
etiology of intracerebral hemorrhage
MUCH-Italy
ABSTRACT
Objective: To test the hypothesis that the effect of antithrombotic medications on the risk of intra-
cerebral hemorrhage (ICH) varies according to the location of the hematoma.
Methods: Consecutive patients with ICH were enrolled as part of the Multicenter Study on Cere-
bral Hemorrhage in Italy (MUCH-Italy). Multivariable logistic regression models served to examine
whether risk factors for ICH and location of the hematoma (deep vs lobar) predict treatment-
specific ICH subgroups (antiplatelets-related ICH and oral anticoagulants [OACs]–related ICH).
Results: A total of 870 (313 lobar ICH, 557 deep ICH) subjects were included. Of these, 223
(25.6%) were taking antiplatelets and 77 (8.8%) OACs at the time of stroke. The odds of
antiplatelet-related ICH increased with aging (odds ratio [OR] 1.05; 95% confidence interval
[CI] 1.03–1.07) and hypertension (OR 1.86; 95% CI 1.22–2.85) but had no relation with the
anatomical location of ICH. Conversely, lobar location of the hematoma was associated with the
subgroup of OAC-related ICH (OR 1.70; 95% CI 1.03–2.81) when compared to the subgroup of
patients taking no antithrombotic medications. Within the subgroup of patients taking OACs,
international normalized ratio (INR) values were higher in those with lobar ICH as compared to
those with deep ICH (2.8 6 1.1 vs 2.2 6 0.8; p 5 0.011). The proportion of patients with lobar
hematoma increased with increasing intensity of anticoagulation, with a ;2-fold increased odds
of lobar compared to deep ICH (odds 2.17; p 5 0.03) in those exposed to overanticoagulation
(INR values .3.0).
Conclusions: OACs, as opposed to antiplatelets, predispose to lobar location of brain hematomas
according to a dose-response relationship. Neurology® 2014;82:529–535
GLOSSARY
BMI 5 body mass index; BP 5 blood pressure; CAA 5 cerebral amyloid angiopathy; CI 5 confidence interval; ICH 5 intra-
cerebral hemorrhage; INR5 international normalized ratio;MUCH-Italy5Multicenter Study on Cerebral Hemorrhage in Italy;
OAC 5 oral anticoagulant.
Antithrombotic medications are a highly effective therapy for the prevention of thromboembolic
strokes in common clinical situations. However, the increasing use of both antiplatelet and oral
anticoagulant (OAC) agents in an aging population has been associated with an increased risk of
intracerebral hemorrhage (ICH),1–4 with the annual incidence ranging from 0.02% to 0.47% in
patients taking a single antiplatelet agent to 0.3%–0.6% in those on OAC therapy.5,6 The
prevention of ICH in patients with antithrombotic medications is therefore critical, and the
identification of risk factors for bleeding is an important practical issue. Data are needed to
determine how specific markers may contribute to individualized risk prediction in order to
make antithrombotics as safe and effective as possible. Several lines of evidence support the
hypothesis that age-related disorders of cerebral small vessels are closely linked to this rare but
devastating complication of antithrombotics use. In other terms, antithrombotic medications
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per se might not cause ICH if cerebral vessels are
intact, but the presence of microangiopathy,
rendering small vessels brittle and fragile, is a
plausible causal or predisposing factor for bleed-
ing. In this regard, sparse reports have suggested
that cerebral amyloid angiopathy (CAA) may be
a stronger predictor of antithrombotic-associated
ICH than hypertensive microangiopathy,7–10
but some recent observations have questioned
this assumption.11,12 Thus, any specific relation
has not yet been established. The Multicenter
Study on Cerebral Hemorrhage in Italy
(MUCH-Italy) provides the opportunity to
investigate this issue owing to its large sample
size, the homogeneous demographic character-
istics and clinical phenotype of the subjects
included, and the standard diagnostic workup.
Therefore, we aimed to evaluate whether 1) an-
tithrombotic medications have differential influ-
ence on specific small cerebral vessel pathology,
using hemorrhage location (deep vs lobar) to
categorize the likely etiology, and 2) any dose-
effect relationship of anticoagulation may fur-
ther predispose to bleeding, in a cohort of Italian
stroke patients with ICH.
METHODS Study group. MUCH-Italy is a countrywide
network of neurologic centers aimed at recruiting patients
with cerebral hemorrhage in the setting of a hospital-based,
multicenter, observational study, as previously described.13 For
the purpose of the present analysis, we screened datasets from
patients with acute ICH consecutively admitted to 4 hospitals
between January 2002 and July 2011. Eligibility for study
participation required neuroimaging (CT or MRI) confirmation
of hemorrhagic stroke. Exclusion criteria included the presence of
trauma, brain tumor, hemorrhagic transformation of a cerebral
infarction, vascular malformation, or any other perceived cause of
secondary ICH. ICH location was assigned based on admission
CT scan by stroke neurologists at each participating center. ICH
isolated to the cortex (with or without involvement of subcortical
white matter) and cerebellar hematomas were defined as lobar
ICH, while ICH selectively involving the thalamus, basal
ganglia, or brainstem was defined as deep (nonlobar) ICH.
Multiple concurrent bleeds involving deep and lobar territories
were defined as mixed ICH and represented an exclusion
criterion. Demographic and clinical information, as well as
neuroimaging data, were collected prospectively and ascertained
by neurologists in each center. International normalized ratio
(INR) was determined in each patient at admission as part of
routine laboratory testing.
Standard protocol approvals, registrations, and patient
consents. The study was approved by relevant local authorities at
each study site. Written informed consent was obtained from all
patients (or next of kin).
Risk factor definition. Subjects were classified as current
smokers if they were currently smoking one or more cigarettes
per day on a regular basis. Hypertension was defined as systolic
blood pressure (BP) .140 mm Hg or diastolic BP .90 mm
Hg out of the acute phase or using pharmacologic treatment
for hypertension. Hypercholesterolemia was considered as choles-
terol.240 mg/dL out of the acute phase or using pharmacologic
treatment to lower blood lipids. Diabetes was defined as fasting
glucose levels .125 mg/dL out of the acute phase or current
treatment with antidiabetic drugs. Body mass index (BMI) was
calculated as weight in kilograms divided by the square of the
height in meters (kg/m2) and subjects dichotomized into obese
(BMI $30.0 kg/m2) and nonobese (BMI ,30.0 kg/m2). Based
on daily alcohol consumption, subjects were dichotomized into
excessive drinkers (.45 g of alcohol) and light to moderate
drinkers/nondrinkers. We also collected information on atrial
fibrillation (medical history or electrocardiographic findings at
admission), atherosclerotic peripheral arterial disease (medical his-
tory), coronary artery disease (medical history of angina, myocar-
dial infarction, coronary artery bypass graft, or percutaneous
transluminal coronary angioplasty), history of previous stroke or
TIA (based on clinical history), and pre-ICH medications
(warfarin, aspirin or other antiplatelet agents, antihypertensive
agents, oral hypoglycemic agents or insulin, and statins).13 Data
were obtained from interviews with patients, next of kin, or
attending physicians or general practitioners.
Statistical analyses. Differences among the treatment groups
(ICHs unrelated to antithrombotic medications, antiplatelet-
related ICHs, and OAC-related ICHs) were examined with the
x2 test, median test, and analysis of variance F test, when
appropriate. Categorical (multinomial) logistic regression model
was performed to examine the conditional effect of risk factors
(hypertension, diabetes, hypercholesterolemia, smoking, alcohol
consumption) and location of the hematoma (deep vs lobar) in
the prediction of ICH subgroups, adjusted for age and sex
(model 1). Since both CAA and hypertensive vasculopathy may
be involved in the pathogenesis of cerebellar hemorrhages,14 we
conducted a separate analysis after exclusion of the cerebellar ICH
cases from the study group, to minimize their potentially
confounding effect (model 2). Finally, in order to investigate
any dose effect of anticoagulant medications, we tested the
impact of specific INR categories (INR # 1.2; 1.2 , INR #
2.0; 2.0 , INR # 3.0; INR . 3.0) on the location of the
hematoma within the subgroup of patients with OAC-related
ICH using the 4 3 2 frequency table. Results are given as ORs
(as measures of disease risk for ICH–covariate associations) with
95% confidence intervals (CIs). A p value, 0.05 on 2-sided test
was considered significant. Data were analyzed using SPSS v. 16
(www.spss.com).
RESULTS A total of 870 patients with ICH fulfilled
the inclusion criteria (mean age 72.4 6 13.0 years;
55.7% male). A total of 313 (36.0%) had lobar ICH,
while 557 (64.0%) had deep ICH. A total of 300
(34.5%) patients were on treatment with antithrom-
botic medications at the time of stroke occurrence,
including 223 (25.6%) patients taking antiplatelet
drugs and 77 (8.8%) taking OACs (5 patients using
a combination of antiplatelet agents and OACs were
categorized as OAC users). No patient was on treat-
ment with other antithrombotic agents (i.e., heparin)
before admission. The characteristics of the study
group are summarized in table 1, stratified by antith-
rombotic medications. Overall, patients treated with
antithrombotics were older and more frequently
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female and had a higher prevalence of risk factors (in
particular, hypertension) and comorbidities (previous
brain ischemia, ischemic heart disease, and atrial
fibrillation) than patients who were not on treatment.
The majority of antiplatelet users were on treat-
ment with aspirin (n 5 207, 90.8%; ticlopidine,
n5 17, 7.5%; clopidogrel, n5 3, 1.3%; aspirin plus
dipyridamole, n 5 1, 0.4%). Among OAC users, 7
(9.1%) had INR values #1.2, 22 (28.6%) had INR
values 1.2–2.0, 29 (37.7%) had INR values 2.0–3.0,
and 19 (24.7%) had INR values.3.0 (figure 1). The
mean INR value in this subgroup was 2.5 6 1.0 and
was higher in patients with lobar ICH as compared to
those with deep ICH (2.8 6 1.1 vs 2.2 6 0.8; p 5
0.011). The mean INR value in the subgroup of
patients exposed to overanticoagulation (INR . 3)
was 4.0 6 0.8.
As summarized in table 2, aging had a similar
effect on increasing the risk of disease in the group
of antiplatelet-related ICH (OR 1.05; 95% CI 1.03–
1.07) as well as in that of OAC-related ICH (OR
1.06; 95% CI 1.03–1.09) when compared to the
reference group of patients who were taking no
antithrombotic medications at the time of stroke occur-
rence. In addition, we observed an increase in the risk
of ICH with hypertension, which was significant only
in the subgroup of patients with antiplatelet-related
ICH (OR 1.86; 95% CI 1.22–2.85). None of the
other traditional vascular risk factors had any indepen-
dent influence on the risk of antithrombotic-related
ICH. Lobar location of the hematoma was associated
with the subgroup of OAC-related ICH (OR 1.70;
95% CI 1.03–2.81), as opposed to what was observed
for deep ICH, while hemorrhage location had no sig-
nificant association with the subgroup of antiplatelet-
related ICH (model 1). Results remained substantially
unchanged when data were reanalyzed after removing
the subgroup of patients with cerebellar hemorrhages
(model 2, not shown). Within the subgroup of
OAC-related ICH, the frequency of ICH increased
in both deep and lobar brain regions with increasing
INR values up to 3.0, with no difference between the 2
Table 1 Demographic and clinical characteristics of the study group
No antithrombotic
therapy (n 5 570)
Antiplatelet-related
ICH (n 5 223)
OAC-related ICH
(n 5 77) p Value
Age, y, mean 6 SD 69.8 6 13.9 77.2 6 9.5 78.1 6 8.8 0.002
Female 239 (41.9) 111 (49.8) 35 (45.5) 0.132
BMI ‡30 kg/m2 202 (35.8) 72 (32.3) 25 (32.5) 0.592
Coronary artery disease 48 (8.5) 69 (31.1) 16 (20.8) ,0.001
Brain ischemia 20 (3.5) 44 (19.8) 17 (22.1) ,0.001
Atrial fibrillation 20 (3.5) 48 (21.6) 50 (66.7) ,0.001
Peripheral arterial disease 13 (2.3) 5 (2.2) 6 (7.8) 0.019
Hypertension ,0.001
Nonhypertensive 152 (26.8) 34 (15.2) 16 (20.8)
Hypertensive on treatment 299 (52.7) 172 (77.1) 52 (67.5)
Hypertensive not on treatment 116 (20.5) 17 (7.6) 9 (11.7)
Diabetes 0.642
Nondiabetic 470 (82.9) 180 (80.7) 59 (76.6)
Diabetic on treatment 69 (12.2) 32 (14.3) 12 (15.6)
Diabetic not on treatment 28 (4.9) 11 (4.9) 6 (7.8)
Cholesterolemia 0.012
Nonhypercholesterolemic 455 (80.2) 171 (76.7) 66 (85.7)
Hypercholesterolemic on treatment
with statins
51 (9.0) 36 (16.1) 9 (11.7)
Hypercholesterolemic not on treatment 59 (10.4) 16 (7.2) 2 (2.6)
Current smoking 83 (14.7) 28 (12.6) 5 (6.5) 0.128
Alcohol, excessive drinking 93 (16.3) 30 (13.5) 11 (14.3) 0.580
ICH location
Deep 377 (66.1) 139 (62.3) 41 (53.2) 0.072
Lobar 193 (33.9) 84 (37.7) 36 (46.8)
Abbreviations: BMI 5 body mass index; ICH 5 intracerebral hemorrhage; OAC 5 oral anticoagulant.
Data are n (%) unless otherwise noted.
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groups (p . 0.05), but it decreased in deep structures
when INR values were .3.0 (p , 0.05; figure 2A).
The proportion of patients with lobar ICH increased
with increasing intensity of anticoagulation according
to a direct dose-response relationship (figure 2B), which
resulted in a ;2-fold increased odds of lobar ICH
compared to deep ICH (odds 2.17; p 5 0.03) in the
subgroup with the highest level of anticoagulation
(INR . 3.0).
DISCUSSION The precise contribution of antith-
rombotic medications to the location of ICH has
not yet been determined. Our study, involving a large
cohort of patients with ICH, indicates that antiplate-
let agents have a negligible influence on the site of
bleeding, their effect probably being overcome by
that of other predisposing conditions, such as aging
and hypertension, while, conversely, the use of OACs
predisposes to lobar location of brain hematomas.
These findings confirm and extend those of previ-
ous studies on the relation between antithrombotic
medications and hemorrhagic stroke and add further
data on the question of whether the contribution of
these agents, especially OACs, to cerebral bleeding
might vary by anatomical location. First, they con-
firm that ICH is common in patients treated with an-
tithrombotic drugs, independent of the anatomical
location of bleeding. Furthermore, in our series like
in prior studies,8,15,16 a relevant proportion of ICH
among those on OACs occurred when the INR values
were in the therapeutic range. Second, they support
previous observations that OAC-related ICHs occur
with a slightly more frequent lobar location.7–10 How-
ever, data on the impact of specific small-vessel arte-
riopathies on OAC-related ICH are scarce, mainly
derived from studies including small case series,
sometimes recording individual history of OAC use
without taking into consideration the intensity of
anticoagulation,7 including patients receiving heparin
at the time of stroke,8,11 or aimed at addressing dif-
ferent issues,8,9,11 with only a few notable excep-
tions.10,12 In this regard, a novel finding from our
data is the evidence of a direct dose-response relation-
ship between OAC treatment and lobar ICH, as illus-
trated by the increasing number of patients in this
subgroup as the INR values increase. We speculate
that OACs affect CAA and hypertensive arterioloscle-
rosis equally when INR values are within the thera-
peutic range, but that they exert a differential impact
on the 2 cerebral microangiopathies, with a greater
effect on cortical-subcortical vessels, in case of exces-
sive anticoagulation. As a consequence of this, there
might be an individual threshold of INR values over
which the influence of OACs on hematoma location
becomes more evident. It remains unclear whether
this is a causal association, or, more likely, the end
result of a dynamic interplay among several condi-
tions including the underlying bleeding-prone
small-vessel disease, the direct effect of these agents
on the clotting cascade, and other unknown factors.
Though unproven, a number of histologic findings
provide biologic support to this view. Arteriolar wall
thinning, interposition of amyloid deposits between
smooth muscle cells, dilated perivascular spaces, and
microaneurysms are frequent findings in CAA involv-
ing lobar brain regions, whereas thickening of the
vessel wall caused by lipohyalinosis in response to
chronic hypertension is the pathologic marker of arte-
riolosclerosis in deep regions. It is likely that these
abnormalities might render cortical-subcortical ves-
sels more vulnerable to rupture and with less potential
for tamponade compared to deep perforating arteries
in the presence of excessive anticoagulation.17,18 In
addition, evidence supporting a link between CAA
and OAC-ICH includes the demonstration that the
APOE e2 allele, a known genetic risk factor of
CAA-related lobar ICH,19,20 is more common in
warfarin-associated ICH than in control patients on
Figure 1 Proportion of patients in various categories of international
normalized ratio values at admission
Within the subgroup of oral anticoagulant–related intracerebral hemorrhage. INR 5 interna-
tional normalized ratio.
Table 2 Conditional effect of age, sex, risk factors (hypertension, diabetes,
hypercholesterolemia, smoking, alcohol consumption), and location of
the hematoma (deep ICH vs lobar ICH) in the prediction of antiplatelet-
related ICH and oral anticoagulant-related ICH (model 1)
Model 1
Antiplatelet-related
ICHs vs non-
antithrombotic-related
ICHs
Oral anticoagulant–
related ICHs vs non-
antithrombotic-related
ICHs
OR 95% CI OR 95% CI
Age, per year 1.05 1.03–1.07 1.06 1.03–1.09
Hypertension 1.86 1.22–2.85 1.31 0.72–2.38
ICH location, lobar vs deep 1.17 0.83–1.64 1.70 1.03–2.81
Abbreviations: CI 5 confidence interval; ICH 5 intracerebral hemorrhage; OR 5 odds ratio.
Only significant values are reported.
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warfarin without ICH,8 and that individual cases of
ICH following anticoagulation or coronary throm-
bolysis revealed advanced CAA on autopsy.21,22 Our
findings are in apparent disagreement with those
derived from the PITCH study by Dequatre-
Ponchelle et al.12 who found no influence of OACs
on the anatomical distribution of ICH but a signifi-
cant effect of these compounds on the volume of deep
brain hematomas. This would support the conclusion
that deep perforating arteries are more sensitive to
anticoagulation than cortical-subcortical vessels. Such
a discrepancy might be explained by the slightly dif-
ferent definition of deep and lobar ICH in the 2
studies, as well as by the potential biases in the mea-
surement of hematoma volumes, as pointed out by
the authors themselves, and, even more important, by
the fact that regression models in the PITCH study
did not include adjustment for hypertension.12
Figure 2 Relation between anatomical location of the hematoma and international normalized ratio values
(A) Percentage of international normalized ratio (INR) values conditional to the location of the hematoma. (B) Percentage of
lobar and deep intracerebral hemorrhages (ICHs) conditional to INR values. (C) 4 3 2 frequency table of lobar/deep ICH by
INR values with odds ratio (OR), 95% confidence interval (CI), and p values for lobar/deep.
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Furthermore, because existing evidence suggests that
both CAA and hypertension can be responsible for
intracranial bleeding in the cerebellum,14 analyses on
the relation between risk factors and ICH location
should consider cerebellar hemorrhages as a potential
source of bias and take account of this.
Several strengths of the present study should be
noted, including the large number of participants,
the homogeneous demographic characteristics and
clinical phenotype of the cohort, and the standard-
ized diagnostic workup and evaluation of risk fac-
tors. Some limitations also should be considered.
First, because the MUCH-Italy is a hospital-
based study, the results might be susceptible to
hospital referral selection bias. However, inaccu-
rate capture of the incident cases is highly unlikely
as all patients with acute cerebral hemorrhage in
the geographic areas involved in the study are usu-
ally referred to the participating centers. Second,
because of the relatively small numbers of subjects
in specific subgroups, such as in the upper INR
strata, some results should be viewed with caution.
Third, recruitment time period was long, during
which improvement in diagnostic facilities and
preventive medications has occurred. In particu-
lar, because brain MRI was not part of the routine
imaging protocol during the first years of the
study, only a small proportion of patients have
these data available. This precluded the inclusion
of neuroradiologic markers that could be of interest,
such as brain microbleeds,23 in the final analysis.
Fourth, we cannot theoretically exclude a classifica-
tion bias in categorizing patients’ medical history or
the potential influence of other, undetected medical
conditions (i.e., chronic kidney disease) on the results
of the study.
In spite of these limitations, our findings provide
evidence that OACs, as opposed to antiplatelet agents,
increase the propensity to cerebral bleeding to a higher
degree in lobar than in deep brain regions. This differ-
ential effect should be considered in future trials with
new antithrombotic agents, as well as with any new
molecules interfering with clot formation and, in clin-
ical practice, when the potential benefits of OACs as
regards stroke prevention are to be balanced against
their bleeding risk. We hypothesize that a similar
effect will be seen with novel OACs or with multiple
antithrombotic therapies, but further dedicated stud-
ies are needed.
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